These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31777965)

  • 1. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    Uchida Y; Nakao M; Tsuji S; Uemura H; Kouyama JI; Naiki K; Motoya D; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
    J Med Virol; 2020 Mar; 92(3):329-338. PubMed ID: 31777965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
    Uchida Y; Nakao M; Yamada S; Tsuji S; Uemura H; Kouyama JI; Naiki K; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
    PLoS One; 2022; 17(2):e0262764. PubMed ID: 35180213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
    Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
    Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
    J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
    Hagiwara S; Nishida N; Ida H; Ueshima K; Minami Y; Takita M; Komeda Y; Kudo M
    J Med Virol; 2019 Oct; 91(10):1804-1810. PubMed ID: 31199513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
    Sato K; Inoue J; Akahane T; Kobayashi T; Sato S; Kisara N; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Masamune A
    Medicine (Baltimore); 2022 Sep; 101(39):e30630. PubMed ID: 36181074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
    Kumada T; Toyoda H; Yasuda S; Ito T; Tanaka J
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e898-e904. PubMed ID: 35048656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
    Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
    BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
    Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
    [No Abstract]   [Full Text] [Related]  

  • 10. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
    Sato K; Inoue J; Akahane T; Kobayashi T; Takai S; Nakamura T; Sato T; Kimura O; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A
    Tohoku J Exp Med; 2022 Nov; 258(4):277-285. PubMed ID: 36244758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B.
    Li MR; Xi HL; Wang QH; Hou FQ; Huo N; Zhang XX; Li F; Xu XY
    PLoS One; 2014; 9(6):e98476. PubMed ID: 24905586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential therapy from entecavir to tenofovir alafenamide
    Itokawa N; Atsukawa M; Tsubota A; Takaguchi K; Nakamuta M; Hiraoka A; Kato K; Abe H; Mikami S; Shimada N; Chuma M; Akito N; Uojima H; Ogawa C; Asano T; Tani J; Morishita A; Senoh T; Yamashita N; Oikawa T; Matsumoto Y; Koeda M; Yoshida Y; Tanabe T; Okubo T; Arai T; Hayama K; Iwashita AN; Kondo C; Tada T; Toyoda H; Kumada T; Iwakiri K
    JGH Open; 2021 Jan; 5(1):34-40. PubMed ID: 33490611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
    Li ZB; Li L; Niu XX; Chen SH; Fu YM; Wang CY; Liu Y; Shao Q; Chen G; Ji D
    Liver Int; 2021 Jun; 41(6):1254-1264. PubMed ID: 33404182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
    Tamaki N; Kurosaki M; Nakanishi H; Itakura J; Inada K; Kirino S; Yamashita K; Osawa L; Sekiguchi S; Hayakawa Y; Wang W; Okada M; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Yasui Y; Tsuchiya K; Takahashi Y; Izumi N
    J Med Virol; 2020 Aug; 92(8):1355-1358. PubMed ID: 31994737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
    Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
    Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
    Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
    Buti M; Marcos-Fosch C; Esteban R
    Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.